Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen S Cox

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The New England Journal of Medicine|November 29, 2008
Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosisHelen S Cox, Katia Sibilia, Silke Feuerriegel, et al.
Plos One|November 19, 2010
Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South AfricaHelen S Cox, Cheryl McDermid, Virginia Azevedo, et al.
Plos One|November 8, 2007
Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failuresHelen S Cox, Stobdan Kalon, Sholpan Allamuratova, et al.
Open Forum Infectious Diseases|June 3, 2015
Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South AfricaHelen S Cox, Johnny F Daniels, Odelia Muller, et al.
Plos Medicine|November 26, 2014
Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trialHelen S Cox, Slindile Mbhele, Neisha Mohess, et al.
Plos One|December 7, 2011
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, IndiaPetros Isaakidis, Helen S Cox, Bhanumati Varghese, et al.
Plos One|July 14, 2012
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, IndiaPetros Isaakidis, Bhanumati Varghese, Homa Mansoor, et al.
The European Respiratory Journal|October 27, 2012
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesDennis Falzon, Neel Gandhi, Giovanni B Migliori, et al.
The Lancet. Global Health|July 19, 2015
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIFGavin J Churchyard, Wendy S Stevens, Lerole D Mametja, et al.
Plos One|October 14, 2009
Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprintsStefan Niemann, Claudio U Köser, Sebastien Gagneux, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The New England Journal of Medicine|November 29, 2008
Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosisHelen S Cox, Katia Sibilia, Silke Feuerriegel, et al.
Plos One|November 19, 2010
Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South AfricaHelen S Cox, Cheryl McDermid, Virginia Azevedo, et al.
Plos One|November 8, 2007
Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failuresHelen S Cox, Stobdan Kalon, Sholpan Allamuratova, et al.
Open Forum Infectious Diseases|June 3, 2015
Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South AfricaHelen S Cox, Johnny F Daniels, Odelia Muller, et al.
Plos Medicine|November 26, 2014
Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trialHelen S Cox, Slindile Mbhele, Neisha Mohess, et al.
Plos One|December 7, 2011
Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, IndiaPetros Isaakidis, Helen S Cox, Bhanumati Varghese, et al.
Plos One|July 14, 2012
Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, IndiaPetros Isaakidis, Bhanumati Varghese, Homa Mansoor, et al.
The European Respiratory Journal|October 27, 2012
Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomesDennis Falzon, Neel Gandhi, Giovanni B Migliori, et al.
The Lancet. Global Health|July 19, 2015
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIFGavin J Churchyard, Wendy S Stevens, Lerole D Mametja, et al.
Plos One|October 14, 2009
Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprintsStefan Niemann, Claudio U Köser, Sebastien Gagneux, et al.
Pageof 2